Pulse Points in Prostate Cancer: Embracing Advances with PARPi Combinations - a podcast by ReachMD

CME credits: 0.75

Valid until: 28-04-2022

Claim your CME credit at https://reachmd.com/programs/cme/pulse-points-prostate-cancer-embracing-advances-parpi-combinations/12472/

During recent years, advances in the understanding of the underlying genetic events and biology in prostate cancer development, including the DDR and MMR pathway alterations, have yielded new avenues for clinical exploration. Prostate cancers with deleterious aberrations in DNA damage repair (DDR) genes, including homologous recombination repair, such as mutations in BRCA1/2 and ATM, are associated with response to poly (adenosine diphosphate–ribose) polymerase (PARP) inhibition.

PARP inhibitors are now gaining FDA approvals for the treatment of patients with mCRPC, and ongoing clinical trials are evaluating these PARP inhibitors as monotherapy or in combination with other treatments such as androgen pathway inhibitors. The National Comprehensive Cancer Network (NCCN®) is now recommending germline testing and molecular biomarker analysis, including tumor testing for HRR mutations, and to consider tumor testing for MSI or dMMR for metastatic disease. PARP inhibitors for the treatment of mCRPC in patients harboring germline and somatic BRCA/ATM mutations, and in combination with androgen pathway inhibition, are poised to propel the management of mCRPC toward a more personalized approach.

In this activity, expert faculty will review, discuss, and provide their expert insights on recent and emerging practice-changing advancements with PARP inhibitors for the treatment of mCRPC, with a ...

Further episodes of ReachMD CME

Further podcasts by ReachMD

Website of ReachMD